Rarity presents poster at Nordic Flow Cytometry
Lei Chen, PhD attended the Nordic Flow Cytometry meeting in Oslo where he presented this poster on the topic of Ultra-sensitive monitoring of leukemia patients using SuperRCA mutation detection assays with Flow Cytometer Readout. Here is the poster – click to enlarge the image.
Safelock is now sRCA, again
The Safelock technology was initially developed under the working title sRCA, or superRCA as in Super Rolling Circle Amplification; super referring to the extra second step of rolling, achieving the outstanding superiority. The technology was then renamed to Safelock. When we realized just how natural the sRCA had become, and that it had stuck with […]
New CEO Linus Bosaeus brings a commercial focus
”We plan to have a fully certified product on the market by 2023, but the method is already being tested in healthcare for use as soon as possible”, says Linus Bosaeus, new CEO of Rarity Bioscience AB in interview on Uppsala University Invest. Read the full article at https://uuinvest.se/precisionsdiagnstik-i-fokus-for-rarity-bioscience/(Article in Swedish)
Lei Chen, Ph.D., co-founder of Rarity Bioscience AB speaks about SafeLock assays on Uppsala University News
Lei Chen, Ph.D., co-founder of Rarity Bioscience AB speaks about SafeLock assays on Uppsala University News. https://www.uu.se/nyheter/artikel/?id=17872&typ=artikel&lang=sv (Text in Swedish)
Rarity Bioscience attends ignite HealthTech 2021
Ignite is an online matchmaking event that addresses the latest challenges of pharma and healthcare, by connecting established companies with providers of disruptive technology solutions. As a provider of a platform that has the potential to disrupt specialist cancer diagnostics, Rarity Bioscience has been invited to matchmaking with several potential partners in research, pharma and […]
Lei Chen, PhD presents Rarity SafeLock at The Global Engage Conference, London, December 7
Co-founder of Rarity Bioscience, Lei Chen, PhD presents Rarity SafeLock, our ultra sensitive targeted mutation detection approach that outperforms ddPCR sensitivity using flow cytometry readout. The presentation includes clinical data from AML patients including mutation-prone high-GC regions. THE RESEARCH & TECHNOLOGY SERIES: qPCR & DIGITAL PCR / LIQUID BIOPSIES / FLOW CYTOMETRY Not attending this […]
Appointment of new CEO
The Board of Rarity Bioscience is pleased to announce the appointment of Linus Bosaeus as the new Chief Executive Officer of Rarity Bioscience with effect from 6th of September 2021. Linus has a background is physics and has been working in the life science industry for the past ten years. In prior positions, his role has […]
Rarity Bioscience secures initial funding and strengthens board of directors
Rarity Bioscience is pleased to announce that the first seed round of has been closed. The funding comes from the founding and management team along with a number of reputable angel investors. The investment will be used for recruitment and the establishment of the first research products. Apart from the funding, this investment also strengthens […]
Rarity Bioscience – a new Landegren company has been established
Rarity Bioscience founded On June 28th, Rarity Bioscience was officially established. The company was founded to commercialize researched results from PhD Lei Chen and Professor Ulf Landegren from Uppsala University and the Department of Immunology, Genetics and Pathology. The company will focus on ultra sensitive detection of rare mutations in liquid biopsy’s, that offers clinicians, researchers and […]